Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,001.00

Eli Lilly and Company (NYSE:LLY) had its price target boosted by BMO Capital Markets from $900.00 to $1,001.00 in a research report report published on Wednesday, Benzinga reports. They currently have an outperform rating on the stock.

A number of other research firms have also recently weighed in on LLY. Truist Financial lifted their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a buy rating in a report on Wednesday. Barclays lifted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an overweight rating in a report on Wednesday, February 7th. Cantor Fitzgerald reissued an overweight rating and set a $885.00 target price (up previously from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday. TheStreet raised shares of Eli Lilly and Company from a c+ rating to a b rating in a research note on Friday, March 8th. Finally, Wells Fargo & Company boosted their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an overweight rating in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $757.95.

Eli Lilly and Company Stock Down 2.8 %

LLY opened at $734.97 on Wednesday. Eli Lilly and Company has a fifty-two week low of $419.80 and a fifty-two week high of $800.78. The company has a debt-to-equity ratio of 1.90, a quick ratio of 0.73 and a current ratio of 1.35. The company has a fifty day moving average of $761.75 and a two-hundred day moving average of $670.56. The stock has a market capitalization of $698.52 billion, a price-to-earnings ratio of 108.24, a PEG ratio of 1.50 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the previous year, the company earned $1.62 earnings per share. The firm’s revenue for the quarter was up 26.0% on a year-over-year basis. On average, research analysts expect that Eli Lilly and Company will post 13.83 earnings per share for the current year.

Hedge Funds Weigh In On Eli Lilly and Company

Institutional investors and hedge funds have recently bought and sold shares of the company. Simon Quick Advisors LLC boosted its holdings in Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after purchasing an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC acquired a new position in Eli Lilly and Company in the 4th quarter valued at about $363,000. Terril Brothers Inc. boosted its holdings in Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after purchasing an additional 429 shares during the last quarter. Hartline Investment Corp boosted its holdings in Eli Lilly and Company by 1.1% in the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock valued at $12,786,000 after purchasing an additional 248 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its holdings in Eli Lilly and Company by 5.2% in the 4th quarter. Commonwealth Equity Services LLC now owns 354,565 shares of the company’s stock valued at $206,683,000 after purchasing an additional 17,461 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.